ObsEva SA: ObsEva Provides Update on Yselty (Linzagolix) Clinical Development Program
- European Medicines Agency Validates Yselty MAA for Uterine Fibroids; US NDA Planned for 1H 2021
- Phase 3 EDELWEISS 3 (Conducted in Europe and US) Study of Yselty for Treatment of Endometriosis is Progressing as Planned; Primary Endpoint Readout Expected 4Q 2021
- Phase 3 EDELWEISS 2 (Conducted in the United States) Yselty Endometriosis Study Discontinued Due to Enrollment Challenges; No Safety Concerns Identified
GENEVA, Switzerland and BOSTON, MA (Jan 11, 2021) - ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women s reproductive health, today announced several important updates on its Yselty program.
Men with localised prostate cancer who reported a baseline dietary pattern that more closely follows the key principles of a Mediterranean-style diet fared bett
Exclusive content, features, opinions and comment - hand-picked by our editors, just for you.
Pick 5 of your favourite companies. Get a daily email with all the news updates on them.
Track the industry of your choice with a daily newsletter specific to that industry.
Stay on top of your investments. Track stock prices in your portfolio.
NOTE :
This product is a monthly auto renewal product.
Cancellation Policy: You can cancel any time in the future without assigning any reasons, but 48 hours prior to your card being charged for renewal. We do not offer any refunds.
To cancel, communicate from your registered email id and send the mail with the request to assist@bsmail.in. Include your contact number for easy reference. Requests mailed to any other ID will not be acknowledged or actioned upon.
WTVR: Can Weight Loss Keep Breast Cancer From Returning?
By Newsy Staff
January 10, 2021
Doctors hope the outcome of the Virginia-based clinical trials will lead to a standard treatment for millions of breast cancer patients.
SHOW TRANSCRIPT